Avita Medical, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Avita Medical, Inc.
Ripples from the COVID-19 pandemic can be felt across Asia Pacific as investment from foreign firms into the region dropped by 45% from 2019 to 2020, and continued its decline in 2021 to 34%.
Three separate agreements team the innovative cancer research center with Takeda, Artios/ShangPharma, and Ziopharm. Hoth continues busy deal-making year by licensing gene therapy from North Carolina State.
The Recell system of Spray-On Skin Cells combined with mesh autografts healed 98% of burns within four weeks in 23 pediatric patients treated under US FDA-approved compassionate use and continued access programs.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2017.
- Medical Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Avita Group, Avita US
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.